This course provides a clinical perspective of PET/CT imaging and the emerging use of Theranostic agents within Nuclear Medicine. A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented.
At the conclusion of this course, participants will be able to:
- Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT
- Describe the logistis of bringing these new diagnostic and therapeutic technologies to clinical practice
- Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging
- Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT
With the recent approval by CMS Medicare for DOTATATE (NETSPOT) PET/CT and the rapid international adoption of targeted Lu-177 based therapies for neuroendocrine and prostate cancers, it is clear that Nuclear Medicine and PET/CT are entering into a new era. New diagnostic and therapeutic agents with remarkable sensitivity and specificity are revolutionizing Nuclear Medicine and Oncology. This course will highlight the latest targeted imaging agents for neuroendocrine and prostate cancers (Ga-68 DOTATATE and Ga-68 PSMA PET/CT) as well as review important core concepts in PET/CT imaging and therapeutic Nuclear Medicine.
This course is intended for practicing radiologists, nuclear medicine physicians and radiologic nurses, physician assistants, technologists, residents, fellows and others who are interested in the clinical applications of PET and PET/CT.
Phillip Kuo, MD, PhD, FACR
Professor of Medical Imaging, Biomedical Engineering, and Medicine
University of Arizona, Tucson, Arizona
Andrew Quon, MD
David Geffen School of Medicine at UCLA
Don C. Yoo, MD
Professor of Diagnostic Imaging, Clinician Educator
The Warren Alpert Medical School of Brown University
Director of Nuclear Medicine, The Miriam Hospital
PET On-Demand 2024
PET On-Demand 2024
- Introduction to Theranostics - Phillip Kuo
- Challenging and Instructive Abdomen and Pelvis PET/CT Review - Don Yoo
- Important of Patient Preparation for PET/CT (Oncology and Cardiac Sarcoidosis) - Don Yoo
- PET/CT in Head and Neck Cancer -Don Yoo
- Update on Radioiodine Treatment for Thyroid Cancer and the Role of PET-CT - Don Yoo
- Nuclear Medicine and Benign Thyroid Disease - Andrew Quon
- Challenging and Interactive Chest PET/CT Review - Don Yoo
- Neuroendocrine Tumor Imaging with DOTA PET/CT - Andrew Quon
- Update on Nuclear Medicine for Infection and Inflammation - Don Yoo
- Lu-177 PSMA Therapy-Lessons from the Vision Trial - Phillip Kuo
- General Nuclear Medicine in 60 Minutes - Andrew Quon
- PET Imaging for the Differential Diagnosis of Dementia - Phillip Kuo
- Dopamine Transporter Imaging of Parkinsonian Syndromes - Phillip Kuo
- Somatostatin Radiotherapy: Our New Era of Nuclear Medicine Therapeutics - Andrew Quon
- Prostate Cancer PET Imaging - Andrew Quon
- Neurotheranostics: Next Frontier for Health Span -Phillip Kuo
- HOW TO CLAIM YOUR CME
Advanced PET On-Demand 2024 - CME Science
Refund Policy: Cancellation and refund requests must be made within 24 hours of purchase. Within the first 24 hours you may cancel and be refunded the full amount of the purchase , less a $100.00 administrative fee. After 24 hours no refunds will be allowed.
Please note: If you have applied for CME credit during this period “NO” refunds will be available.
Important Notice Regarding Copyright and Usage
All materials purchased from CME Science are protected by copyright and are for the sole personal use of the purchaser.
Distributing, forwarding, transferring, reproducing, or reselling these educational materials in any way is strictly prohibited and constitutes copyright infringement. This includes, but is not limited to, sharing them with others, posting them online, or incorporating them into other products or services.
Your license to access these materials is non-transferable and applies only to you, the original purchaser.
We reserve the right to terminate or restrict your access to our service, without prior notice, if we find any violation of these terms and conditions.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Partners for Advancing Clinical Education (PACE) and CME Science. Partners for Advancing Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Partners for Advancing Clinical Education (PACE) designates this enduring material for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosure of Conflicts of Interest
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
|Conflicts of Interest
|Phillip Kuo, MD, PhD, FACR
Consultant and/or speaker for Amgen, Bayer, Blue Earth Diagnostics, Chimerix, Eisai, Fusion Pharma, General Electric Healthcare, Invicro, Novartis, Radionetics, and UroToday. He is a recipient of research grants from Blue Earth Diagnostics and General Electric Healthcare.
|Andrew Quon, MD
Has no relevant financial relationship(s) with ineligible companies to disclose
|Don C. Yoo, MD
Consultant, Invicro LLC
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CME Science planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Computer System Requirements
Any internet accessible device.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional information about the accreditation of this activity, please visit https://partnersed.com